CMS recently announced that its self-developed innovative drug, the INHBE small RNA therapeutic CMS-D008, received a drug clinical trial approval notice from China's National Medical Products Administration on March 4, 2026. The drug is intended for clinical trials in individuals who are overweight or obese. CMS-D008 is a subcutaneously administered siRNA drug designed to reduce lipid accumulation by targeting and inhibiting the expression of the inhibin subunit beta E gene in the liver. The proportion of overweight and obese adults globally is projected to reach 50% by 2030, providing a solid foundation for the market potential of CMS-D008.